<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-85063</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Pulmonary Tuberculosis Associated to Adalimumab: a Study of 3 Cases</dc:title>
<dc:description xml:lang="en">Tumour necrosis factor-alpha antagonist drugs represent a significant advance in the treatment of inflammatory diseases, such as rheumatoid arthritis, spondyloarthropathies, and intestinal inflammatory disease. The increase in tuberculosis with infliximab is known, but there is less data available that specifically associates tuberculosis with adalimumab. We present the cases of 2 patients with rheumatoid arthritis and one patient with ankylopoietic spondylitis on treatment with adalimumab, who developed pulmonary and disseminated tuberculosis despite following the screening and prophylaxis measures recommended in guidelines. We also review the association between treatment with tumour necrosis factor-alpha antagonists and tuberculosis (AU)</dc:description>
<dc:creator>Núñez Delgado, Manuel</dc:creator>
<dc:creator>Guerra Valesa, José Luis</dc:creator>
<dc:creator>Blanco Pérez, José J</dc:creator>
<dc:creator>Aranda Torres, Ángel</dc:creator>
<dc:creator>Pego Reigosa, José M</dc:creator>
<dc:creator>Temes Montes, Enrique</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los fármacos antagonistas del factor de necrosis tumoral alfa representan un importante avance en el tratamiento de enfermedades inflamatorias como la artritis reumatoide, las espondiloartropatías y la enfermedad inflamatoria intestinal. Se reconoce el incremento de tuberculosis con infliximab, pero disponemos de menos datos que relacionen la tuberculosis específicamente con adalimumab. Presentamos los casos de 2 pacientes con artritis reumatoide y un paciente con espondilitis anquilopoyética en tratamiento con adalimumab, que desarrollaron tuberculosis pulmonar y diseminada a pesar de seguir las medidas de cribado y profilaxis recomendadas por las guías, y revisamos la asociación entre el tratamiento con antagonistas del factor de necrosis tumoral alfa y tuberculosis (AU)</dc:description>
<dc:source>Arch Bronconeumol;46(4): 203-205, abr. 2010. graf, ilus</dc:source>
<dc:identifier>ibc-85063</dc:identifier>
<dc:title xml:lang="es">Tuberculosis pulmonar en relación con adalimumab: estudio de 3 casos</dc:title>
<dc:subject>^d29622</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d14798^s22016</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d13550^s22012</dc:subject>
<dc:subject>^d1178^s22038</dc:subject>
<dc:subject>^d14798^s22054</dc:subject>
<dc:subject>^d14798^s22012</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d13550^s22038</dc:subject>
<dc:subject>^d1178^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201004</dc:date>
</metadata>
</record>
</ibecs-document>
